GDF15 and MELAS: In 2015, Tanaka et al.40used GDF‐15 to assess the efficacy of pyruvate in 2SD hybrid cells (with MELAS‐causing mutations) and control cells, identifying GDF‐15 as a promising therapeutic indicator.